N/A N=53 Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE)
Dementia, Alzheimer Type
Primary: Feasibility: Recruitment Rate — 4.1 participants recruited per month
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 IVIG (Gamunex-C) Treatment Study for POTS Subjects
Postural Tachycardia Syndrome
Primary: Change in Symptoms Measured by Change in COMPASS-31 Score (After Initial Treatment Phase) — -5.5; -10.6 score on a scale — p=0.629
Phase 1 N=11 Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer.
Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal Neoplasms
Primary: Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 0; 0 Participants
N/A N=12 Prehabilitation of Frail Surgical Cancer Patients Using Remote Ischemic Preconditioning
Colon Cancer · Fragility · Prehabilitation
Primary: 6 Minute Walk Test Distance (Pre Surgery) — 369; 432 Meters
Phase 2 N=126 Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer
Limited Stage Small Cell Lung Cancer
Primary: Progression Free Survival (PFS) — 12.6; 13.2; 9.5 Months
Phase 2 N=103 A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma
Indolent Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) According to the 2007 Revised International Working Group (IWG) Criteria — 65.3; 52.9; 62.2; 54.3 percentage of participants
Phase 2 N=16 Probiotics, Immune Function, and the Brain in Alcohol Consumers
Alcohol; Use, Problem
Primary: Lipopolysaccharide Binding Protein (LBP) — 23609.2; 28111.9 ng/ml — p=0.1183
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
N/A N=81 Cognitive Training for PTSD
Posttraumatic Stress Disorder
Primary: Clinician Administered PTSD Scale - Reexperiencing — 2.6; 2.96 score on a scale
Phase 1 N=15 Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
Biological Availability · Healthy Participants
Primary: AUCinf of Nirmatrelvir Following the Administration of 4 Different Nirmatrelvir/Ritonavir FDC Tablets (Test Formulations) Compared to the Nirmatrelvir/Ritonavir…
N/A N=770 Strategies to Assist With Management of Pain
Chronic Low Back Pain
Primary: Composite Pain Severity — 5.6; 5.6 score on a scale
N/A N=131 Mechanisms of Severe Acute Influenza Consortium (MOSAIC)
Influenza
Primary: Number of Patients With Clinical Phenotype Presenting Also a Sequential Activation of Immune/Infammatory Pathways. — 131 Participants
N/A N=16 Clinical Investigation on the Blood Oxygenation at the Optic Nerve Head in Fabry Patients
Fabry Disease
Primary: Blood Oxygenation at the Optic Nerve Head — 60.8; 65.3 percentage of oxygen saturation
Phase 4 N=6,128 Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years
Herpes Zoster
Primary: Incidence Rate of Confirmed Herpes Zoster (HZ) Cases — 0.0; 8.2 Cases per 1000 person-years — p=<0.0001
N/A N=64 Virtual Reality Compared to Screen Based Engagement on Mood
Virtual Reality
Primary: Change in Positive Affect and Negative Affect From Baseline to After a 2 Minute Mood Induction — 3.7; 4.63; 1.97; 1.56 units on a scale